116 related articles for article (PubMed ID: 30339745)
41. Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes.
Bonander N; Jamshad M; Hu K; Farquhar MJ; Stamataki Z; Balfe P; McKeating JA; Bill RM
Biochem Soc Trans; 2011 Apr; 39(2):537-40. PubMed ID: 21428935
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition.
Li Q; Sodroski C; Lowey B; Schweitzer CJ; Cha H; Zhang F; Liang TJ
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7620-5. PubMed ID: 27298373
[TBL] [Abstract][Full Text] [Related]
43. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB.
Bruening J; Lasswitz L; Banse P; Kahl S; Marinach C; Vondran FW; Kaderali L; Silvie O; Pietschmann T; Meissner F; Gerold G
PLoS Pathog; 2018 Jul; 14(7):e1007111. PubMed ID: 30024968
[TBL] [Abstract][Full Text] [Related]
45. Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection.
Lavie M; Linna L; Moustafa RI; Belouzard S; Fukasawa M; Dubuisson J
Traffic; 2019 Oct; 20(10):753-773. PubMed ID: 31328852
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C Virus Mimics Effects of Glypican-3 on CD81 and Promotes Development of Hepatocellular Carcinomas via Activation of Hippo Pathway in Hepatocytes.
Xue Y; Mars WM; Bowen W; Singhi AD; Stoops J; Michalopoulos GK
Am J Pathol; 2018 Jun; 188(6):1469-1477. PubMed ID: 29577937
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of Structural Tuning of the Hepatitis C Virus Human Cellular Receptor CD81 Large Extracellular Loop.
Cunha ES; Sfriso P; Rojas AL; Roversi P; Hospital A; Orozco M; Abrescia NGA
Structure; 2017 Jan; 25(1):53-65. PubMed ID: 27916518
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
49. Virology: Final entry key for hepatitis C.
Pietschmann T
Nature; 2009 Feb; 457(7231):797-8. PubMed ID: 19212389
[No Abstract] [Full Text] [Related]
50. Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models.
Mekky RY; El-Ekiaby N; El Sobky SA; Elemam NM; Youness RA; El-Sayed M; Hamza MT; Esmat G; Abdelaziz AI
Arch Virol; 2019 Jun; 164(6):1587-1595. PubMed ID: 30949812
[TBL] [Abstract][Full Text] [Related]
51. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection.
Yoshida T; Takayama K; Kondoh M; Sakurai F; Tani H; Sakamoto N; Matsuura Y; Mizuguchi H; Yagi K
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):119-24. PubMed ID: 22093821
[TBL] [Abstract][Full Text] [Related]
52. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.
Sekhar V; Pollicino T; Diaz G; Engle RE; Alayli F; Melis M; Kabat J; Tice A; Pomerenke A; Altan-Bonnet N; Zamboni F; Lusso P; Emerson SU; Farci P
PLoS Pathog; 2018 Mar; 14(3):e1006916. PubMed ID: 29538454
[TBL] [Abstract][Full Text] [Related]
53. Claudin-1 and its potential role in HCV entry: another piece of the puzzle.
Hamilton JP; Thuluvath PJ
J Clin Gastroenterol; 2008 Jan; 42(1):3-4. PubMed ID: 18097281
[No Abstract] [Full Text] [Related]
54. Hepatitis C Virus Infection of Cultured Cells and Primary Human Hepatocytes.
Lowey B; Li Q
Curr Protoc Cell Biol; 2018 Sep; 80(1):e54. PubMed ID: 30058773
[TBL] [Abstract][Full Text] [Related]
55. Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry.
Gerold G; Meissner F; Bruening J; Welsch K; Perin PM; Baumert TF; Vondran FW; Kaderali L; Marcotrigiano J; Khan AG; Mann M; Rice CM; Pietschmann T
Cell Rep; 2015 Aug; 12(5):864-78. PubMed ID: 26212323
[TBL] [Abstract][Full Text] [Related]
56. Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts.
Cukierman L; Meertens L; Bertaux C; Kajumo F; Dragic T
J Virol; 2009 Jun; 83(11):5477-84. PubMed ID: 19297469
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors.
Burlone ME; Budkowska A
J Gen Virol; 2009 May; 90(Pt 5):1055-1070. PubMed ID: 19264629
[TBL] [Abstract][Full Text] [Related]
58. Nuclear receptor 4 group A member 1 determines hepatitis C virus entry efficiency through the regulation of cellular receptor and apolipoprotein E expression.
Zhu W; Pei R; Jin R; Hu X; Zhou Y; Wang Y; Wu C; Lu M; Chen X
J Gen Virol; 2014 Jul; 95(Pt 7):1510-1521. PubMed ID: 24744301
[TBL] [Abstract][Full Text] [Related]
59. Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1.
Sugiyama M; Kanto T
Hepatology; 2016 Sep; 64(3):979-82. PubMed ID: 27405253
[No Abstract] [Full Text] [Related]
60. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.
Zhang J; Randall G; Higginbottom A; Monk P; Rice CM; McKeating JA
J Virol; 2004 Feb; 78(3):1448-55. PubMed ID: 14722300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
